MSC-Exos in the Treatment of Erectile Dysfunction
Mesenchymal stem cell-derived exosomes (MSC-Exos) are promising in the treatment of some types of erectile dysfunction in a rat model.
J Cell Mol Med. 2019 Sep 11. doi: 10.1111/jcmm.14615. [Epub ahead of print]
Liu Y1, Zhao S1,2, Luo L1, Wang J1, Zhu Z1, Xiang Q1, Deng Y1, Zhao Z1.
- Department of Urology & Andrology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Department of Urology, Zhejiang Taizhou Central Hospital (Affiliated Hospital of Taizhou University), Taizhou, China.
Erectile dysfunction (ED) is a common ageing male’s disease, and vascular ED accounts for the largest proportion of all types of ED. One of the mechanisms of vascular ED in the clinic is arterial insufficiency, which mainly caused by atherosclerosis, trauma and surgical. Moreover, oxidative stress damage after tissue ischemia usually aggravated the progress of ED. As a new way of acellular therapy, mesenchymal stem cell-derived exosomes (MSC-Exos) have great potential in ED treatment. In the current study, we have explored the mechanism of MSC-Exos therapy in a rat model of internal iliac artery injury-induced ED. Compared with intracavernous (IC) injection of phosphate-buffered saline after artery injury, of note, we observed that both mesenchymal stem cells (MSCs) and MSC-Exos through IC injection could improve the erectile function to varying degrees. More specifically, IC injection MSC-Exos could promote cavernous sinus endothelial formation, reduce the organization oxidative stress damage, and improve the nitric oxide synthase and smooth muscle content in the corpus cavernosum. With similar potency compared with the stem cell therapy and other unique advantages, IC injection of MSC- Exos could be an effective treatment to ameliorate erectile function in a rat model of arterial injury.
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
PMID:31512385 DOI: 10.1111/jcmm.14615